Recurrence Versus New Primary After Cervical Cancer Treatment
A 47-year-old woman treated 3 years ago for FIGO IB2 squamous cell carcinoma of the cervix with chemoradiation and brachytherapy presents with a 3 cm vaginal apex mass and a 2 cm left pelvic sidewall mass. Biopsy of the vaginal mass shows squamous cell carcinoma. PET-CT shows uptake in the vaginal apex and left pelvic sidewall but no distant disease. Her original tumor was HPV16 positive; the new biopsy is also HPV16 positive. The abstractor must decide whether to record a recurrence or a new primary.
1. What criteria distinguish a recurrence from a new primary in this setting, and how should the abstractor apply them?
Read the worked answer
The distinction rests on timing, anatomic relationship to the original tumor, and histologic/molecular concordance.
Criteria applied:
- Timing: A 3-year interval is within the typical recurrence window for cervical cancer; late recurrences occur but a new primary is less likely within this interval.
- Anatomic pattern: Vaginal apex and pelvic sidewall involvement is the expected pattern of locoregional recurrence after chemoradiation for IB2 disease; a new primary would more typically arise in a different site (e.g., new cervical/vaginal primary after a different histology or HPV type).
- Histology and HPV type: Both original and new tumors are squamous cell carcinoma and HPV16 positive. Concordance supports recurrence rather than a second independent HPV-driven primary, though HPV typing alone is not definitive.
- Conclusion: Record as recurrence of the original cervical primary, not a new primary. The abstractor should not create a new primary record unless the physician documents a new primary or the site/histology clearly differs.
2. How should the recurrence be captured in the registry, and what fields are essential?
Read the worked answer
Capture the recurrence as an event linked to the original primary.
Essential fields:
- Date of recurrence (first evidence, e.g., biopsy or imaging date).
- Site of recurrence: vaginal apex and pelvic sidewall (locoregional).
- Method of detection: biopsy and PET-CT.
- Histology confirmation: squamous cell carcinoma, HPV16 positive.
- Treatment of recurrence: document planned salvage therapy (e.g., pelvic exenteration or systemic therapy) as it becomes available.
- Disease-free interval: 3 years from completion of primary treatment.
Data-quality notes:
- Do not alter the original stage or diagnosis date.
- Ensure the recurrence is not double-counted as a new primary.
- Link recurrence to the original record per registry linkage rules.
3. What follow-up and survival reporting considerations apply to this case?
Read the worked answer
Follow-up and survival reporting:
- Survival status: The patient is alive with disease at recurrence; update vital status and recurrence fields.
- Disease-free and overall survival: Calculate disease-free interval from end of primary treatment to recurrence date; overall survival from diagnosis date.
- Follow-up completeness: Ensure subsequent follow-up captures response to salvage therapy and any distant progression.
- Reporting accuracy: Recurrence should be reported as locoregional, not distant, based on current imaging; if distant disease develops, update site fields.
- Avoid misclassification: Do not report as a second primary in survival analyses, which would distort both the original cohort's recurrence rate and the new-primary incidence.